DISCLAIMER — Not financial advice. Educational content only, not an offer or solicitation to buy or sell any security. Biotech and small/mid-cap stocks are highly speculative and volatile and can result in a partial or total loss of capital. Do your own research and consult a licensed advisor where appropriate. / Contenuti a solo scopo informativo e didattico, non costituiscono consulenza finanziaria né offerta o sollecitazione al pubblico risparmio ai sensi delle normative CONSOB e SEC. Le azioni biotech e le small/mid cap sono strumenti altamente speculativi e volatili e possono comportare la perdita parziale o totale del capitale investito. Si raccomanda di effettuare sempre le proprie ricerche e, se necessario, di rivolgersi a un consulente abilitato.
Read / Leggi Disclaimer

Weekly Market Recap & Outlook for May 25–29, 2026: Memorial Day, Iran/Hormuz, Warsh Fed, Core PCE and the AI Earnings Test

weekly 25-29 may

The week ahead starts with U.S. markets closed for Memorial Day on Monday, May 25, then moves quickly into a dense calendar: Consumer Confidence, Marvell, Salesforce, Snowflake, Synopsys, Dell, Costco, GDP, durable goods and the Fed’s preferred inflation gauge. The setup is constructive but fragile: AI infrastructure remains the leadership engine, Iran/Hormuz headlines can move oil and inflation expectations, and Kevin Warsh’s first days at the Fed put rate sensitivity back at the center of the tape.

Natera, Inc. (Nasdaq: $NTRA): A Full Deep Dive Into the cfDNA Platform, Signatera Momentum, FDA CDx Validation, Fetal Focus, Prospera and the Next Catalyst Stack

NTRA

Natera has moved far beyond the simple label of a prenatal genetic-testing company. The 2026 story is now a scaled precision-diagnostics platform built around oncology MRD, women’s health, organ transplant monitoring, rare-disease genomics, data generation, reimbursement expansion, and industrial-scale sequencing infrastructure.

Immuneering Corporation (Nasdaq: $IMRX): ASCO Survival Update Turns Atebimetinib Into a High-Stakes Pancreatic Cancer Story

IMRX

Immuneering’s latest survival update gives traders a fresh reason to focus on $IMRX: 17.3 months median overall survival in first-line metastatic pancreatic cancer, an ASCO oral presentation on June 1, a pivotal Phase 3 trial now recruiting, and a cash runway guided into 2029. The opportunity is real, but so are the small-cap biotech risks.

EagleNXT / AgEagle Aerial Systems (NYSE American: $UAVS): U.S.-Made eBee VISION, Army Awards and the Counter-Drone Pivot

UAVS

A full Merlintrader deep dive on UAVS: the company’s transition from an agricultural and mapping-drone vendor into a defense, public-safety, sensor and counter-drone platform; the recent U.S. Army orders; the Allen, Texas manufacturing shift; the ThirdEye USA counter-UAS venture; the Aerodrome loitering-munition option; the financial reality behind the headlines; and the catalysts that can decide whether this remains a speculative micro-cap story or becomes a more credible U.S.-made unmanned-systems supplier.

MetaVia Inc. (Nasdaq: $MTVA): ADA Late-Breaking Posters, DA-1726 Obesity Signal, and the Financing Wall Behind the Run

MTVA

MetaVia is trying to place itself inside one of the hottest areas in biotech: obesity, MASH and next-generation cardiometabolic drugs. The story is interesting because DA-1726 has early human weight-loss data and fresh ADA visibility. The story is dangerous because the company is tiny, cash is limited, dilution risk is real, and the next major value test is still clinical execution, not social-media excitement.

Regeneron Pharmaceuticals (Nasdaq: $REGN): Melanoma Setback Reopens the 2026 Growth Debate

regnmay e1779191829525

Regeneron Pharmaceuticals is not a fragile biotech story. It is one of the most successful U.S. biotechnology companies of the last two decades, with a deep research culture, internally built technology platforms, a historic ophthalmology franchise around Eylea, a massive immunology engine through Dupixent with Sanofi, and a growing ambition in oncology. That is exactly why the latest melanoma setback matters. The issue is not whether Regeneron can survive one failed study. The real question is

The Smart Money Is Buying These 3 Small Caps Before Anyone Notices: $IMSR, $BHVN, $AVLN

institu e1779138194367

Institutional Money Is Loading 3 Small Caps — $IMSR, $BHVN, $AVLN | Merlintrader Merlintrader — Institutional Flows Q1 2026 The Smart Money Is Buying These 3 Small Caps Before Anyone Notices: $IMSR, $BHVN, $AVLN Finviz Elite screener data and recent public-market activity highlight three tickers — $IMSR, $BHVN, $AVLN — where institutional ownership, 13F filings, […]

BriaCell Therapeutics Corp. (Nasdaq: $BCTX): Phase 3 Breast Cancer, ASCO 2026 And A Rapid Pipeline Expansion

bctxmay26 e1779133645751

Merlintrader Deep Dive Updated May 18, 2026 Biotech / Immuno-Oncology BriaCell Therapeutics Corp. (Nasdaq: $BCTX): Phase 3 Breast Cancer, ASCO 2026 And A Rapid Pipeline Expansion BriaCell is no longer only a tiny Phase 3 metastatic breast cancer binary. Since the last Merlintrader deep dive, the company has added new clinical sites, reported a larger […]

Fortress Biotech (Nasdaq: $FBIO): Q1 2026 Turns the Story Into a Portfolio-Model Test

FBIOmay2026update e1779115607404

Fortress Biotech is one of the more unusual stories in the U.S. small-cap biotech universe because it should not be analyzed like a normal single-drug development company. FBIO is a biopharma platform that creates, finances, controls or participates in multiple companies and programs, trying to monetize value through product revenue, royalties, milestones, asset sales, equity stakes and strategic transactions. That structure makes the stock more complicated than a classic biotech catalyst trade.

SolarEdge Technologies (Nasdaq: $SEDG): Turnaround, Nexis, Storage and the Profitability Test

SEDG

SolarEdge is no longer just a classic residential solar inverter story. The current investment debate is about whether the company can convert its 2025 restructuring, inventory normalization and product refresh into a durable return to profitable growth. Q1 2026 gave bulls enough material to argue that the worst of the cycle may be behind the company: revenue grew 46% year over year, gross margin held above 20%, free cash flow remained positive, and Q2 guidance pointed to another sequential improvement. But the bear case has not disappeared

Defense Stocks Weekly Recap: Ondas, Karman and Red Cat Show Why the Drone-Defense Trade Is No Longer Just a Theme ($ONDS, $KRMN, $RCAT)

defense recap

This week’s defense tape gave traders a useful reminder: the drone-defense and dual-use aerospace trade is alive, but it is no longer a simple “buy the theme” market. The strongest moves are now being separated by revenue quality, backlog visibility, margin path, balance-sheet needs and whether companies can convert battlefield relevance into funded, repeatable commercial execution.